Premium
THE EFFECT OF LISURIDE HYDROGEN MALEATE IN THE HYPERPROLACTINAEMIA‐AMENORRHOEA SYNDROME: CLINICAL AND HORMONAL RESPONSES
Author(s) -
CECCO L.,
FOGLIA G.,
RAGNI N.,
ROSSATO P.,
VENTURINI P.L.
Publication year - 1978
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1978.tb01506.x
Subject(s) - lisuride , hyperprolactinaemia , medicine , endocrinology , prolactin , anovulation , ovulation , menstruation , menstrual cycle , hormone , polycystic ovary , diabetes mellitus , bromocriptine , insulin resistance
SUMMARY Eleven women with secondary amenorrhoea and hyperprolactinaemia were treated with lisuride, a new semisynthetic ergot derivative. Acute administration of lisuride (100 μg orally) significantly suppressed serum prolactin (PRL) levels in nine out of eleven subjects. In these nine patients, prolonged treatment with lisuride (50–200 μg daily) lowered PRL levels into the normal range, menstrual cycles were resumed and eight patients ovulated. Two patients, in whom lisuride failed to lower PRL levels into the normal range, did not resume normal menstruation. These data demonstrate that lisuride may be used clinically to lower PRL levels and to restore cyclic gonadotrophin secretion and ovulation in amenorrhoeic patients with hyperprolactinaemia.